Grgurević, Department of Proteomics, University of Zagreb, School of Medicine, Šalata 2, 10000 Zagreb, Croatia,
Croat Med J. 2023 Dec 31;64(6):430-435. doi: 10.3325/cmj.2023.64.430.
To determine the characteristics of patients who experienced muscle fasciculations and migraine auras without headache after BNT162b2 immunization.
In January 2022, we published a case report that described a 48-year-old female patient who experienced muscle twitching and migraine auras without headache following BNT162b2 immunization. A self-administered online survey was sent to people who had written to us and complained of similar symptoms described in the case report (N=20).
The survey was completed by 11 participants, of whom 10 reported muscle twitching following BNT162b2 immunization lasting a median of 14 (4-36.5) days. Five of these participants (50%) reported migraine auras without headache. Participants further reported on self-identified triggers that altered the intensity of their symptoms, such as anxiety or caffeine. Fifty percent of participants who got an acute SARS-CoV-2 infection (3/6) experienced increased muscle symptom intensity during the acute phase of the disease.
To the best of our knowledge, our survey is the first to summarize patients' experiences of these phenomena occurring after BNT162b2 immunization. It is important to note that no causal relationship between vaccination and these phenomena can be inferred.
确定接种 BNT162b2 后出现肌肉抽搐和偏头痛先兆但无头痛的患者特征。
2022 年 1 月，我们发表了一份病例报告，描述了一名 48 岁女性患者在接种 BNT162b2 后出现肌肉抽搐和偏头痛先兆但无头痛。我们向曾向我们写信并抱怨与病例报告中描述的类似症状的人发送了一份自我管理的在线调查（N=20）。
共有 11 名参与者完成了调查，其中 10 名报告在接种 BNT162b2 后出现持续中位数为 14（4-36.5）天的肌肉抽搐。其中 5 名参与者（50%）报告出现偏头痛先兆但无头痛。参与者进一步报告了自我识别的触发因素，这些因素改变了他们症状的强度，如焦虑或咖啡因。在急性 SARS-CoV-2 感染的 6 名参与者中（3/6），有 50%的参与者在疾病的急性阶段经历了肌肉症状强度的增加。
据我们所知，我们的调查是首次总结接种 BNT162b2 后出现这些现象的患者的经验。需要注意的是，不能推断接种疫苗与这些现象之间存在因果关系。
